Intellia Therapeutics Inc (NASDAQ:NTLA) saw a downside of -3.40% to close Friday at $32.39 after subtracting -$1.14 on the day. The 5-day average trading volume is 869,700 shares of the company’s common stock. It has gained $35.88 in the past week and touched a new high 1 time within the past 5 days. An average of 779,205 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 756,854.
NTLA’s 1-month performance is -15.54% or -$5.87 on its low of $32.37 reached on 09/22/23. The company’s shares have touched a 52-week low of $32.44 and high of $63.12, with the stock’s rally to the 52-week high happening on 06/14/23. YTD, NTLA has lost -7.17% or -$2.50 and has reached a new high 12 times. However, the current price is down -48.69% from the 52-week high price.
Insider Transactions
NTLA stock investors last saw insider trading activity on Jul 31.Bhanji Muna (Director) most recently sold 265 shares at $42.33 per share on Jul 31. This transaction cost the insider $11,217. Director, Bhanji Muna, sold 1,867 shares at a price of $39.30 on Jul 06. Then, on Jul 03, EVP, Chief Technical Officer Clark Eliana sold 360 shares at a price of $40.51 per share. This transaction amounted to $14,584.
Valuation Metrics
NTLA stock has a beta of 1.85. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 54.04 while the price-to-book (PB) in the most recent quarter is 2.59.
Intellia Therapeutics Inc’s quick ratio for the period ended June 29 was 9.41, with the current ratio over the same period at 9.41. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.10, while the total debt to equity was 0.11. In terms of profitability, the gross margin trailing 12 months is 84.54%. The trailing 12-month EBITDA margin is -864.51% while for the period ending June 29, Intellia Therapeutics Inc’s operating margin was -867.11%. The firm’s gross profit as reported stood at $510.29 million against revenue of $52.12 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 18.6% to -$123.68 million, while revenue of -$103.13 million was 16.62% off the previous quarter. Analysts expected NTLA to announce -$1.32 per share in earnings in its latest quarter, but it posted -$1.4, representing a -6.10% surprise. EBITDA for the quarter stood at more than -$130.16 million. NTLA stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 218.35 million, with total debt at $122.33 million. Shareholders hold equity totaling $88.49 million.
Let’s look briefly at Intellia Therapeutics Inc (NTLA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 15.46% to suggest the stock is trending oversold, with historical volatility in this time period at 21.33%.
The stock’s 5-day moving average is $33.86, reflecting a -9.58% or -$3.43 change from its current price. NTLA is currently trading -13.67% above its 20-day SMA, -14.18% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -29.25% and SMA200 by-22.90%.
Stochastic %K and %D was 6.15% and 7.13% and the average true range (ATR) pointed at 1.20. The RSI (14) points at 22.10%, while the 14-day stochastic is at 0.32% with the period’s ATR at 1.23. The stock’s 9-day MACD Oscillator is pointing at -1.56 and -2.68 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Intellia Therapeutics Inc (NASDAQ: NTLA), Canaccord Genuity launched coverage with a Buy rating. Analysts offering their rating for NTLA stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate NTLA as a “sell,”, while 4 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 3 rates the stock as overweight while 21 have offered a “buy” rating.
What is NTLA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $38.00 and a high of $157.00, with their median price target at $81.00. Looking at these predictions, the average price target given by analysts is for Intellia Therapeutics Inc (NTLA) stock is $84.00.
